← Return to all swing-trade opportunities
ZBH — Oversold Bullish Reversal
Status: Watch
Scanner score: 20.0/100
Why this was flagged
ZBH was identified as a bullish technical setup based on the Oversold Bullish Reversal pattern. The scanner found a score of 20.0/100 using trend alignment, momentum, price action, volume, and risk-management rules.
Trade framework
Position-sizing example
These examples use the distance between the reference entry and stop-loss. They do not account for commissions, slippage, taxes, overnight gaps, or your personal account size.
Exit plan
- Stop-loss: Exit if the stop-loss is reached. Do not move the stop farther away to avoid taking the planned loss.
- Target 1: Consider taking partial profit when Target 1 is reached and reducing risk on the remaining shares.
- Target 2 or trailing exit: Consider closing the remaining position at Target 2, or use a disciplined trailing stop only if the trend remains strong.
- Time exit: Reassess or close a trade that fails to progress within the suggested holding window.
Technical chart
Daily closing price with moving averages and planned trade levels. This chart is a screening aid, not a guarantee of future results.
$1,000 educational outcome examples
These examples use a $1,000 position and fractional shares at the midpoint of the entry zone. Actual results can differ because of market gaps, fills, spreads, commissions, taxes, slippage, and changing conditions.
Easy explanation for new investors
Recent news context
This automated review is separate from the technical score. It summarizes recent related articles and does not predict price movement.
Overall context: Caution (Moderate confidence)
Zimmer Biomet (ZBH) is trading at $93.50, technically identified as an oversold bullish reversal. Recent news highlights internal organizational changes and sector-wide pressures. The company promoted several executives to lead its Americas commercial transformation, although this follows the departure of Group President Kevin Thornal. Insider selling by an SVP occurred, and ZBH shares fell 4.6%, attributed to a broader medical device sector risk-off trade rather than company-specific issues. A competitor's supply problems and an unrelated FDA clearance by Shoulder Innovations provide mixed industry context. The coverage is mixed, with leadership transitions and market sentiment outweighing limited positive specific news.
Potentially supportive context
- The company announced leadership promotions to accelerate its U.S. go-to-market transformation and drive growth.
- Analysts maintain a consensus Hold rating with an average price target of $104.42.
- The stock recently reported strong quarterly earnings that beat analyst estimates.
Risks and caution items
- Group President Kevin Thornal is departing as part of a position restructuring.
- SVP and Chief Legal Officer Chad Phipps sold 3,000 shares in a non-10b5-1 transaction.
- The stock experienced a 4.6% decline linked to a broader medtech risk-off trade.
- A competitor faced supply disruptions and slower sales due to cyberattacks and market headwinds.
Latest reviewed article: Sep 10, 2026 8:32 pm
Recent related articles
Shoulder Innovations Inc. received 510(k) clearance from the U.S. Food and Drug Administration for its N-22 Humeral Head, a titanium implant for patients with metal hypersensitivity. This new implant, designed for anatomic total shoulder arthroplasty, complements their existing N-22 Glenosphere and addresses…
Stryker's stock fell 9.7% after CFO Preston Wells reported ongoing supply issues in its peripheral vascular business, stemming from a March cyberattack, and unexpectedly slower hip sales. The company had hoped to resolve the supply disruptions by the third quarter, but they…
Chad F. Phipps, SVP, Chief Legal & Corporate Affairs Officer of Zimmer Biomet, sold 3,000 common shares on September 4, 2026, at $98.35 per share, totaling $295,050. This transaction reduced his direct holdings to 65,231 shares. The information was generated by AI…
Chad Phipps, an insider at Zimmer Biomet (NYSE:ZBH), sold 3,000 shares of the company's stock for approximately $295,050 on September 4th, reducing his direct ownership by 4.4%. The company recently reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend.…
Chad F. Phipps, Senior Vice President, Chief Legal & Corporate Affairs Officer and Secretary at Zimmer Biomet, sold 3,000 shares of ZBH common stock for approximately $295,050. Following the sale, he directly holds 65,231 shares, which include shares acquired through an Employee…
Zimmer Biomet (ZBH) stock fell 4.6% today, likely due to a broader "medtech risk-off trade" rather than company-specific news. The drop is attributed to investors reacting to negative updates in the wider medical device sector and reassessing supply-chain and execution risks among…
Zimmer Biomet has announced key leadership promotions within its Americas and Global Business Group organizations to enhance focus and agility. Gary Campbell is promoted to President, Americas, Brian Hatcher to President, Recon, S.E.T., CMFT, Neuro and Biosurgery, and Bradley Kessler to President,…
Zimmer Biomet announced that Kevin Thornal, Group President, Global Businesses and the Americas, will be departing the company effective September 30, 2026. His departure is due to a position restructuring and he will receive severance benefits as per the company's Restated Executive…
Important: Some returned articles may describe competitors, industry conditions, or related companies. Open the source before relying on an article.
Scanner confirmations
- RSI is near oversold territory with bullish candle confirmation.